Antioxidants in the Treatment of Graves Disease

Guerra, Liliana N.; Moiguer, Silvia; Karner, Mirta; Molina, Ma del Carmen Rios de; Sreider, Claudia M.; Burdman, J. A.

doi:10.1080/15216540152122102

Cited by 38 publications

(33 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plasma MDA levels with hyperthyroidism prior to treatment to be significantly higher than control group, with the levels decreasing after treatment [20]. Consistent with other studies [21,22], in our study MDA levels were higher in patients with hyperthyroidisms compared to control group ( heart, hepatic and brain tissue [23,24]. It is known that lipid peroxidation and generation of ROS leads to oxidative stress and damage.…”

Section: Resultssupporting

confidence: 81%

Evaluation of Oxidative Stress Status and Adenosine Deaminase Activity in Hyperthyroid and Hypothyroid Patients

Kıran

Karabulut²,

Şahin³

et al. 2014

Med-Science

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 81%

Evaluation of Oxidative Stress Status and Adenosine Deaminase Activity in Hyperthyroid and Hypothyroid Patients

Kıran

Karabulut²,

Şahin³

et al. 2014

Med-Science

View full text Add to dashboard Cite

show abstract

“…In this case, by externally providing antioxidant molecules, the possibility of preventing the development progression of overt hypothyroidism in HT should be considered and prospective studies should be planned in this direction. Likewise, positive effects of antioxidant treatment in Graves' patients on Graves' progression and complications have been shown before (28).…”

Section: European Journal Of Endocrinologymentioning

confidence: 99%

The relationship between oxidative stress and autoimmunity in Hashimoto's thyroiditis

Ateş

Yılmaz

Altay

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: We have aimed to study the relation between Hashimoto's thyroiditis (HT) and thyroid autoantibodies and oxidative stress parameters in euthyroid, subclinical and overt hypothyroid stages. Design and methods: A total of 124 patients were included in the study; 93 of whom were newly diagnosed with HT (31 patients in each of the euthyroid, subclinical hypothyroid and overt hypothyroid subgroups), aged over 18 and had not received any prior treatment and 31 of whom were healthy volunteers. Results: Total oxidant status (TOS) and oxidative stress index (OSI) levels were higher, and total antioxidant status (TAS) and total thiol and arylesterase levels were lower in the overt hypothyroid group compared to other groups. TOS and OSI levels increased, and TAS levels decreased significantly in each phase from euthyroid, subclinical hypothyroid, to overt hypothyroid subgroups among HT patients. There was a negative correlation between TAS, log (paraoxonase1) and paraoxonase1/HDL and anti-thyroid peroxidase and a negative correlation between anti-thyroglobulin and total thiol. It was also determined that overt hypothroidism was an individual predictor that effects all of the oxidative stress parameters, but not total thiol, levels. Conclusion: Our results suggest that oxidative stress increases continuously during the development of subclinical hypothyroidism and overt hypothyroidism in patients with HT. To determine whether this is a cause or result, randomized, controlled trials that study the effect of antioxidant treatment on the development of overt hypothyroidism and its consequences, e.g., increase in total cholesterol levels, may be performed in euthyroid and/or subclinical hypothyroid patients with HT.

show abstract

“…2A), the resident macrophages of the liver (29,39). In man, hyperthyroidism is characterized by significant changes in circulating parameters related to oxidative stress, including (i) higher levels of lipid peroxidation indicators (40)(41)(42)(43)(44)(45)(46)(47)(48)(49); (ii) enhancement in hydrogen peroxide and lipid hydroperoxide levels (49); and (iii) diminished levels of antioxidants such as a-tocopherol (41), coenzyme Q (44), ascorbic acid (41), and reduced thiols (42,46,50). These changes correlated with the enhancement in urinary lipid peroxidation products (40) and chemiluminescence response (51) and are either significantly reduced or normalized by thyrostatic therapy or antioxidant supplementation (40-46, 49, 50).…”

Section: T 3 -Induced Enhancement Of Liver O 2 Consumption and Oxidatmentioning

confidence: 99%

Hormetic responses of thyroid hormone calorigenesis in the liver: Association with oxidative stress

Videla

2010

IUBMB Life

View full text Add to dashboard Cite

SummaryThyroid hormone (L-3,3 0 ,5-triiodothyronine, T 3 ) exerts calorigenic effects by accelerating mitochondrial O 2 consumption through transcriptional activation of respiratory genes, with consequent increased reactive oxygen species (ROS) production. In the liver, ROS generation occurs at different sites of hepatocytes and in the respiratory burst of Kupffer cells, triggering the activation of the transcription factors nuclear factor-jB, signal transducer and activator of transcription 3, and activating protein 1. Under these conditions, the redox upregulation of Kupffer cell-dependent expression of cytokines [tumor necrosis factor-a, interleukin (IL)-1, and IL-6] is achieved, which upon interaction with specific receptors in hepatocytes trigger the expression of antioxidant enzymes (manganese superoxide dismutase, inducible nitric oxide synthase), antiapoptotic proteins (Bcl-2), and acute-phase proteins (haptoglobin, b-fibrinogen). These responses and the promotion of hepatocyte and Kupffer cell proliferation observed represent hormetic effects re-establishing redox homeostasis, promoting cell survival, and protecting the liver against ischemia-reperfusion (IR) injury. It is proposed that hormesis underlying T 3 action may constitute a novel preconditioning strategy for IR injury during liver surgery in man or in liver transplantation using reduced-size grafts from living donors, considering that (i) with the exception of the controversial ischemic preconditioning, all other studied strategies have failed to reach the clinical setting and (ii) T 3 is a well-tolerated therapeutic agent that either lacks major adverse effects or has minimal and controlled side effects. IUBMBIUBMB Life, 62(6): [460][461][462][463][464][465][466] 2010

show abstract

Antioxidants in the Treatment of Graves Disease

Cited by 38 publications

References 0 publications

Evaluation of Oxidative Stress Status and Adenosine Deaminase Activity in Hyperthyroid and Hypothyroid Patients

Evaluation of Oxidative Stress Status and Adenosine Deaminase Activity in Hyperthyroid and Hypothyroid Patients

The relationship between oxidative stress and autoimmunity in Hashimoto's thyroiditis

Hormetic responses of thyroid hormone calorigenesis in the liver: Association with oxidative stress

Contact Info

Product

Resources

About